Maria Fardis

Maria Fardis is currently Chairman & Chief Executive Officer at Lassen Therapeutics, Inc. since 2023, Chief Executive Officer at Airnexis Therapeutics, Chairman & Chief Executive Officer at Lassen Therapeutics LLC, Chairman at Obsidian Therapeutics, Inc. since 2022, Independent Director at CRISPR Therapeutics AG since 2022, Director at Quanta Therapeutics, Inc., Director at Kartos Therapeutics, Inc., and Venture Partner at Frazier Management LLC since 2021.
Former roles include President, Chief Executive Officer & Director at Iovance Biotherapeutics, Inc. from 2016 to 2021, Associate Director-Project & Portfolio Management at Gilead Sciences, Inc. in 2012, Director at Alliance for Regenerative Medicine, Chief Oncology Operations & Alliances at Pharmacyclics LLC from 2013 to 2014, and Chief Operating Officer at Acerta Pharma LLC and Acerta Pharma BV from 2015 to 2016.
Education includes an MBA from Golden Gate University in 2007, a doctorate from the University of California, Berkeley in 1998, and an undergraduate degree from the University of Illinois At Urbana–Champaign in 1992.